Recurrent deep vein thrombosis (DVT) presents a significant risk of morbidity and mortality. Once a patient experiences an initial episode, the likelihood of recurrence is notably elevated without appropriate long-term secondary prevention. At the center of recurrence prevention are personalized anticoagulation regimens, risk factor modification, and clinical monitoring, particularly in those with unprovoked DVT or
Cytomegalovirus (CMV) is a widespread herpesvirus with the potential to cause severe disease in immunocompromised individuals, including organ transplant recipients, HIV-infected patients, and newborns infected in utero. While typically asymptomatic in healthy individuals, CMV reactivation or primary infection in vulnerable hosts can result in life-threatening organ involvement, graft rejection, or congenital complications. The prevention of
Cytomegalovirus (CMV) is a critical opportunistic infection in individuals with advanced HIV infection, particularly those with CD4 counts below 50 cells/µL. CMV primarily manifests as CMV retinitis, the most common cause of blindness in AIDS patients, though it may also present as esophagitis, colitis, pneumonitis, or encephalitis. Effective prevention of CMV disease in advanced HIV
Cytomegalovirus (CMV) is a major cause of infectious complications following solid organ transplantation. Its presence not only results in direct effects—such as CMV syndrome and tissue-invasive disease—but also exerts indirect effects, including allograft rejection, opportunistic infections, and long-term graft dysfunction. The prevention of CMV disease after organ transplant must be proactive, risk-adapted, and supported by
Cytomegalovirus (CMV) remains one of the most significant viral infections in renal transplant recipients. CMV infection following kidney transplantation not only causes direct disease but also contributes to indirect effects such as acute rejection, graft dysfunction, and opportunistic infections. Effective prevention of CMV disease after kidney transplantation is critical for improving both short-term and long-term
Cytomegalovirus (CMV) is the most common opportunistic infection following cardiac transplantation. It is associated with direct effects such as CMV syndrome and tissue-invasive disease, as well as indirect consequences including graft rejection, allograft vasculopathy, and increased mortality. The prevention of CMV disease after cardiac transplantation is essential to ensure both graft and patient survival. A
Cisplatin remains a cornerstone chemotherapeutic agent for treating various solid tumors, including testicular, ovarian, head and neck, and lung cancers. However, its clinical efficacy is compromised by dose-limiting toxicities, notably ototoxicity, which manifests as irreversible, bilateral sensorineural hearing loss. The incidence of cisplatin-induced ototoxicity (CIO) varies from 20% to over 60%, with children and the
Cidofovir, a nucleotide analog with broad-spectrum antiviral activity, is a potent agent used in the treatment of cytomegalovirus (CMV) retinitis and other DNA virus infections, particularly in immunocompromised patients. Despite its efficacy, cidofovir’s clinical utility is significantly limited by its high nephrotoxic potential. Without appropriate preventive strategies, the drug can cause irreversible kidney injury, necessitating
Chemotherapy-induced neurotoxicity, particularly peripheral neuropathy, is a frequent and often dose-limiting complication of cancer treatment. This form of neurotoxicity primarily affects sensory nerves and is commonly associated with agents such as platinum compounds, taxanes, vinca alkaloids, and proteasome inhibitors. Preventing neurotoxicity not only preserves functional integrity but also ensures uninterrupted and effective oncologic treatment. Understanding
Chemotherapy-induced mucositis is a debilitating inflammatory condition of the mucosal lining of the gastrointestinal tract, most commonly manifesting in the oral cavity. It significantly compromises nutritional intake, causes intense pain, increases infection risk, and often necessitates chemotherapy dose reductions or delays. Given its profound impact on patient outcomes and quality of life, implementing effective preventive